SOP DC0020.1
Hybridoma Development Initiation
Page 1 of 4
Version: 2
Effective Date: June 1, 2015
Hybridoma Project Initiation Checklist
Date:
Company Name:
Primary Contact:
Secondary Contact:
Phone:
Fax:
Phone:
E-mail:
E-mail:
Bill to:
Ship to:
Fax:
Project Goals:
Please describe the overall goals for the antibodies you would like MBS to develop. Please include the attributes that you
want the antibodies to have (for example, specificity) as well as the format(s) in which you plan to use the antibodies in
your final application.
Do you have any information and/or past experience with raising an antibody response against this target?
 Yes  No
If YES, please describe:
Specify any known homology with
endogenous mouse proteins:
Cross reactants of concern:
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com
Page 2 of 4
SOP DC0020.1
Hybridoma Development Initiation
Version: 2
Effective Date: June 1, 2015
Reagent Information:
Please provide details for all possible immunogen and screening reagents available to support the project.
1
Reagent:
Purpose:
 Protein
Type of antigen:
Description:  Purified
 Peptide
 Lysate
 Carbohydrate
 Immunogen  Screening  Other
 Other:
 Other:
% purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other:
Expression System (if applicable):
 Bacterial
Accession #
Strain:
 Mammalian Cell Line:
 Other:
Amount available:
2
MW:
 Lyophilized
Reconstitution:
 In Solution
Buffer:
Concentration:
Reagent:
Purpose:
 Protein
Type of antigen:
Description:  Purified
Storage:  -80C  -20C  4C
pI:
 Peptide
 Lysate
 Carbohydrate
 Immunogen  Screening  Other
 Other:
 Other:
% purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other:
Expression System (if applicable):
 Bacterial
Accession #
Strain:
 Mammalian Cell Line:
 Other:
Amount available:
3
MW:
 Lyophilized
Reconstitution:
 In Solution
Buffer:
Concentration:
Reagent:
Purpose:
 Protein
Type of antigen:
Description:  Purified
Storage:  -80C  -20C  4C
pI:
 Peptide
 Lysate
 Carbohydrate
 Other:
 Other:
% purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other:
Expression System (if applicable):
 Bacterial
 Immunogen  Screening  Other
Accession #
Strain:
 Mammalian Cell Line:
 Other:
Amount available:
MW:
 Lyophilized
Reconstitution:
 In Solution
Buffer:
pI:
Storage:  -80C  -20C  4C
Concentration:
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com
SOP DC0020.1
Hybridoma Development Initiation
Page 3 of 4
Version: 2
Effective Date: June 1, 2015
Antibody Controls:
Please provide information about any positive control antibodies available to support the project.
1
Antibody Description:
 Customer can provide
 Please order if needed - Supplier/Cat No:
Immunogen (if known):
Species source:
 Mouse
Form:  Purified
 Antiserum
 Rabbit
 Goat
 Other:
 Goat
 Other:
 Other:
Use information:
2
Antibody Description:
 Customer can provide
 Please order if needed - Supplier/Cat No:
Immunogen (if known):
Species source:
 Mouse
Form:  Purified
 Antiserum
 Rabbit
 Other:
Use information:
Specify what types of samples you would like provided for internal evaluation:
 No internal work planned. All antibody samples remain at MBS for characterization and selection.
 Purified hybridoma fusion product samples, discovery-scale (0.5mg average yield)
 Corresponding set of antibody-biotin conjugates to support matched pair studies
 15mL overgrown supernatants from cryopreserved hybridoma fusion products
 3-5mL supernatants from cryopreserved hybridoma fusion products
 Other:
Please describe any planned assay work with these samples:
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com
Page 4 of 4
SOP DC0020.1
Hybridoma Development Initiation
Version: 2
Effective Date: June 1, 2015
Hybridoma Development Timeline
MBS recommends purifying
hybridoma fusion supernatants by
MultiPure to allow for advanced
screening and better identification
of lead candidates for subcloning
Immunization
~4 weeks
Discovery grade monoclonal antibody
samples are characterized further for
end application clone selection and
production.
Fusion
Subcloning
~4 weeks
~4 weeks
Hybridoma Development ~12 weeks
Optional (in vitro)
Antibody Production
~4 weeks
Optional (Ascites)
Antibody Production
~Additional 4 weeks
Antibody Production ~ 4-8 weeks (method dependent)
Hybridoma Development Terms of Service
Maine Biotechnology Services offers over 25 years of hybridoma development and screening expertise. Our goal is
to achieve the maximum level of satisfaction for all of our customers; however it is impossible to offer an absolute
guarantee that we can develop a monoclonal antibody to every immunogen or meet the specific goals originally
outlined. MBS guarantees that we keep our customers informed of project status and involve them at all critical
points. In-process check points allow us to strategize with the customer when needed, increasing the chance for
success. Customers have the ability to terminate the project at any point and will not be invoiced for work that was
not performed.
Hybridoma development batch records are well maintained. All information and resulting product is confidential
and the property of the customer.
Thank you for choosing MBS.
MBS Hybridoma Development Staff
Our experienced hybridoma development team will stay in contact with you throughout your project.
Contact
Position
E-mail
Phone Ext:
Carrie Rice
Director of Sales
crice@mainebiotechnology.com
14
Abby Culberson
Sales Account Manager
aculberson@mainebiotechnology.com
10
Nathalie Forster
Hybridoma Project Manager
nforster@mainebiotechnology.com
27
Moira Reno
Lab Manager
mreno@mainebiotechnology.com
24
MAINE BIOTECHNOLOGY SERVICES, INC.
1037R Forest Avenue Portland, Maine 04103 USA
800-925-9476 > 207-797-5454 > FAX: 207-797-5595
email: sales@mainebiotechnology.com www.mainebiotechnology.com